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Amphetamine-type substance related presentations to the Emergency Department 
Mental Health Team of a Local Health District in Australia  
 
Abstract 
Objectives: To identify the prevalence and profile of amphetamine type substance (ATS) 
related presentations to the Emergency Department Mental Health Team (EDMHT) of a 
Local Health District in Australia.  
Methods: Data was collected from medical records of all ATS presentations to the EDMHT 
over a one-year period, between 1 January 2015 and 31 December 2015. 
Results: Of all presentations referred to the EDMHT, 0.15% (N=189) were ATS related. Of 
these the majority were male, the average age was 32, 19.0% engaged in intravenous drug 
use, some were aggressive and 15.9% required tranquilisation. The most common presenting 
issues were psychosis and suicidal threats, intent, and behaviour (including intentional 
overdose). Multiple comorbid conditions were identified. On discharge 34.4% were admitted 
into a psychiatric hospital and 32.8% were referred to Community Mental health teams.  
Conclusions:  ATS users suffer from multiple comorbidities and pose a significant burden on 
emergency services.  





According to the 2010 Global Burden of disease study there were 17.2 million amphetamine 
dependent people world over, in 2010 (1), with this number rising significantly between 2002 
and 2014, especially among young adults (2, 3). Australasia was identified as having the 
second highest amphetamine dependence, behind the Asian regions (1). Amphetamine-type 
substances (ATS) are stimulant drugs, with the most popular ones amongst recreational users 
including amphetamine, methamphetamine, phentermine, 3,4-methylenedioxyamphetamine 
(MDA), 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxy-N-
ethylamphetamine (MDEA)(4). Stimulant use is associated with significant harms and 
comorbidities such as suicide attempts, homelessness, imprisonment, depression and anxiety 
(5). ATS users present a significant burden to hospital Emergency Departments (ED) (6); 
they present with a range of issues, particularly aggression and agitation, and tend to be less 
cooperative compared to other toxicology related presentations (7).  
 
This study identified the prevalence and profile of ATS related presentations referred to the 
ED mental health team (EDMHT) of a Local Health District in Australia. ATS presentations 
are referred to the EDMHT from ED (usually from ED triage) if there are confirmed or 
suspected comorbid mental health concerns. The aim of this study was to gain insight into the 




A retrospective file review was undertaken, of all ATS related presentations to the EDMHT 
of the Central Coast Local Health District (CCLHD), over a one-year period, between 1 
January 2015 and 31 December 2015. CCLHD is situated in a peri-urban area of New South 
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Wales, Australia, and includes two EDs situated at Gosford and Wyong hospitals, serving a 
population of 333,119, with a combined annual census of 124,904 in 2015. In ED, cases of 
substance use are referred to the EDMHT for review when mental health issues are identified 
at triage or by ED staff. At each ED there is an EDMHT available 24 hours a day to provide 
specialised management alongside medical care in ED (8). The EDMHT maintains a log of 
patients referred for drug related presentations, from which ATS users for inclusion were 
identified. All presentations to the EDMHT determined to be related to recent ATS use were 
included. ATS use was self-reported in most cases on history taking (but some were 
identified on urine drug screen or on collecting collateral history). The first author examined 
the electronical medical records (eMR) of identified patients and extracted data in relation to 
presenting issue, sex, age, legal status, accommodation status, criminal history, all 
tranquiliser use in ED, opioid substitution therapy, length of stay for those hospitalised, 
seclusion and restraint use, comorbid disorders (in relation to the current presentation), 
current comorbid substances of abuse as recorded on that specific presentation (not the reason 
why they presented to ED), and discharge destination from ED. The collected data was 
pooled, entered into an Excel spreadsheet and IBM SPSS software was used for statistical 




There was a total of 189 ATS related presentations seen by the EDMHT. This is 0.15% of all 
ED presentations during that period (124,904 ED presentations), at a rate of 16 per month. 
The average age was 32 (minimum 17 maximum 59, SD 9.29 years), 85.2% (n = 161) were 
aged 40 and below, and 71.4% (n = 135) were male. At presentation, 11.6% (n = 22) were 
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scheduled by a police officer and 3.7% (n = 7) were scheduled by an ambulance officer under 
the NSW Mental Health Act 2007 while 84.7% (n = 160) were voluntary presentations. A 
criminal history (conviction by a court of law or police charges as self-reported or reported 
from collateral sources of information during that specific presentation to ED) was identified 
in 31.2% (n = 59) and 12.7% (n = 24) were homeless. Some ATS users were on opioid 
substitution therapy, with 6.9% (n = 13) on methadone and 2.6% (n = 5) on Suboxone. Table 
1, lists the presenting issues.  
 
Insert Table 1  
 
As per Table 2 and 3, patients presented with a range of comorbid mental and physical health 
concerns and substances of abuse.  
 
Insert Table 2 
Insert Table 3 
 
Tranquilisers were used in ED in at least 15.9% (n = 30) presentations and 14.8% (n = 28) 
required parenteral sedation (see table 4).   
 
Insert Table 4 
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Table 5 outlines discharge destinations from ED (after assessment by EDMHT). For those 
admitted into a psychiatric hospital (34.4%, n = 65), the average length of stay was 12.2 days 
(minimum 1 maximum 88, SD 16.3 days) and for those admitted into a drug and alcohol unit 
(3.2%, n = 6) the average length of stay was 3 days (minimum 1 maximum 5, SD 1.6 days). 
The rates of seclusion and restraint among ATS users admitted into a psychiatric hospital 
were 12.3% (n = 8) and 10.8% (n = 7) respectively.  
Insert Table 5 
 
Discussion 
ATS users seen by EDMHT constituted 0.15% of all presentation to ED, which is lower than 
rates reported in the literature of around 1% (7, 9). This is most likely because not all ATS 
presentations to the ED are referred to the EDMHT. Our finding that most ATS presentations 
were male is consistent with previous research that indicates that at least two thirds of ATS 
users are male (5, 7). We found that users were relatively young (average age of 32, with the 
majority under 40) which is also consistent with the literature (2, 9), and indicates a need for 
interventions specifically targeting males under the age of 40. Almost a third (31.2%) of 
presentations were identified as having a criminal history (any conviction or police arrest), 
which is comparable to other findings that show that 17.2% of ATS presentations had 
previously been jailed (5). Some of our presentations were homeless (12.2%) compared to 
21.9% reported by another Australian study (5).  
Consistent with the existing literature, our study found that ATS presentations to the EDMHT 
occurred in the context of comorbid mental illness (5, 9). ATS related EDMHT presentations 
were most likely to occur in the context of suicidality or intentional overdose (31.8%) and 
this is consistent with evidence that shows that people with stimulant use disorders report 
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high rates of suicidality (5). The 2007 National Survey of Mental Health and Wellbeing 
found that 31.7% of respondents with a lifetime stimulant use disorder reported suicidal ideas 
(5). However, not all studies capture such high rates of suicidal ideation in this population; a 
Californian study identified only 10.5% of ATS users as suicidal (10), and an Australian 
study from Perth found that only 6.4% of amphetamine-related ED presentations were 
suicidal (9). While it is unclear why there is such variation between studies, it is likely that 
our approach where drug related ED presentations with identified mental health issues are 
assessed by a specialist mental health team is highly effective at identifying mental health 
concerns.  
The prevalence of psychosis identified here (34.4%) is similar, albeit a little higher, to  
findings reported in the literature of 27% (7) and 26% (11) and this could be due to our study 
examining patients referred to the EDMHT only. Our study reports relatively low rates of 
aggression in ATS ED presentations (12.2%), at least in comparison to some of the literature. 
The rates of ATS user aggression in Australian EDs reported in the literature ranges from 
8.3% in an ED in Perth (9) to 65.4% in a Melbourne ED (12). In terms of sedation, our 
finding that 15.9% of ATS presentations received tranquilisers (with 14.8% requiring 
parenteral tranquilisers) is low in comparison to 32% reported in the literature (9). We 
identified lower rates of intravenous drug use (19.0%) than reported by other studies (71%) 
(9).  
A high proportion of ATS related presentations were admitted to either a mental health 
inpatient facility (34.4%) or a drug and alcohol unit (3.2%), and this is consistent with 
evidence from California that shows that 35.0% of ATS related ED presentations required 
admission in 2016 (10). More users were referred for follow up by community mental health 
teams (CMHT) than follow up by a general practitioner (GP) (1.1%) or by community drug 
and alcohol services. Follow up by mental health services is based on a more assertive 
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approach compared to the latter where patients have to proactively contact a GP or drug and 
alcohol services. As there is no means of ensuring patients will comply with the latter, a high 
rate of referral to CMHT may ensure greater patient safety and better outcomes. Since users 
suffer from various comorbidities(10), this identifies missed opportunities to engage them at 
a primary health level. However, it is also possible that most ATS users do not have 
identifiable GPs and other clinicians/CMHT can still refer patients to GPs and drug and 
alcohol services on follow up.  
While our study contributes to the literature in relation to the profile of ATS presentations to 
the EDMHT, a number of limitations need to be noted. The data was collected by various 
clinicians working under the fluctuating pressures of the ED, ATS was self-reported in most 
cases and users with acute medical or surgical issues were not referred to the EDMHT 
thereby creating potential information bias.  The data is limited to one Local Health District 
of NSW and as such limited in the extent to which it can be generalised. There may also be 
confounding factors that have not been controlled for, e.g. presentations of psychosis/suicide 
may not necessarily be related to ATS use. 
 
Conclusion  
Our study outlines the profile of ATS related presentations to the EDMHT of a Local Health 
District in a peri-urban area of NSW and contributes to a body of literature that highlights the 
burden of ATS presentations. High rates of psychosis, suicidality, intravenous drug use, 
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Table 1. Presenting complaint of ATS users at presentation to EDMHT* 
Variable Number 
Psychosis 34.4% (n = 65) 
Suicidal 27.0% (n = 51) 
Aggression 12.2% (n = 23) 
Other complaints 6.3% (n = 12) 
Intentional overdose 4.8% (n = 9) 
Intoxication 4.2% (n = 8) 
Anxious 3.2% (n = 6) 
Depression 2.6% (n = 5) 
Self-inflicted lacerations 2.1% (n = 4) 
Homicidal 1.6% (n = 3) 
Seeking detoxification 0.5% (n = 1) 
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Poor sleep 0.5% (n = 1) 
Failure to cope  0.5% (n = 1) 




Table 2. Primary comorbid disorders* in ATS users relevant to the current 
presentation  
Comorbidity Number 
Intravenous drug use (IVDU) 19.0% (n = 36)                            
Personality disorder 14.8% (n = 28) 
Hepatitis C 14.3% (n = 27) 
Schizophrenia 9.5% (n = 18) 
Depression 9.0% (n = 17) 
Attention-Deficit Hyperactivity Disorder 
(ADHD) 
9.0% (n = 17) 
Bipolar disorder 6.3% (n = 12) 
Anxiety 4.8% (n = 9) 
Chronic pain 3.7% (n = 7) 
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Seizures/epilepsy 3.2% (n = 6) 
Schizoaffective disorder 2.6% (n = 5) 
Oppositional defiant disorder (ODD) 1.6% (n = 3) 
HIV 0.5% (n = 1) 
Conduct disorder 0.5% (n = 1) 
Gambling addiction 0.5% (n = 1) 
Pornography addiction 0.5% (n = 1) 





















Table 3. Comorbid substances of abuse  
Substance of abuse Number 
Cannabis 51.3% (n = 97) 
Alcohol 38.6% (n = 73) 
Tobacco  28.6% (n = 54) 
Heroin 9.0% (n = 17) 
Benzodiazepines 7.9% (n = 15) 
Prescription opioids 7.4% (n = 14) 
Cocaine 2.6% (n = 5) 
Lysergic acid diethylamide (LSD) 1.1% (n = 2) 
Methadone 1.6% (n = 3) 
Pregabalin 1.6% (n = 3) 
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Testosterone 1.1% (n = 2) 
y-hydroxybutyrate (GHB) 0.5% (n = 1) 
Ketamine 0.5% (n = 1) 
Olanzapine 0.5% (n = 1) 




Table 4. Tranquiliser use in ED*  
Benzodiazepine tranquiliser treatment in ED 
- parenteral/oral 
13.8% (n = 26) / 15.9% (n = 30)  
Antipsychotic tranquiliser treatment in ED – 
parenteral/oral 
14.8% (n = 28)/ 11.1% (n = 21) 
*Some patients received both oral and parenteral, or both benzodiazepines and antipsychotics 
tranquilisers. Tranquilisers were used to manage aggressive patients, but also to manage 















Table 5. Discharge destination from ED*  
Outcome Number 
Psychiatric admission 34.4% (n = 65) 
Adult community mental health team  30.7% (n = 58) 
Outpatient drug and alcohol services  11.6% (n = 22) 
No follow up arrangements documented 6.9% (n = 13) 
Drug and alcohol admission 3.2% (n = 6) 
Referred to other medical specialties  3.2% (n = 6) 
Police custody 3.2% (n = 6) 
Absconded from ED 2.6% (n = 5) 
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Youth community mental health team 2.1% (n = 4) 
GP  1.1% (n = 2) 
Social worker 1.1% (n = 2) 
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